Bacterial biofilm contributes to antibiotic resistance. Developing antibiofilm agents, more favored from natural origin, is a potential method for treatment of highly virulent multidrug resistant (MDR) bacterial strains; The potential of Pimenta dioica and Pimenta racemosa essential oils (E.Os) antibacterial and antibiofilm activities in relation to their chemical composition, in addition to their ability to treat Acinetobacter baumannii wound infection in mice model were investigated; P. dioica leaf E.O at 0.05 µg·mL⁻¹ efficiently inhibited and eradicated biofilm formed by A. baumannii by 85% and 34%, respectively. Both P. diocia and P. racemosa leaf E.Os showed a bactericidal action against A. baumanii within 6h at 2.08 µg·mL⁻¹. In addition, a significant reduction of A. baumannii microbial load in mice wound infection model was found. Furthermore, gas chromatography mass spectrometry analysis revealed qualitative and quantitative differences among P. racemosa and P. dioica leaf and berry E.Os. Monoterpene hydrocarbons, oxygenated monoterpenes, and phenolics were the major detected classes. β-Myrcene, limonene, 1,8-cineole, and eugenol were the most abundant volatiles. While, sesquiterpenes were found as minor components in Pimenta berries E.O; Our finding suggests the potential antimicrobial activity of Pimenta leaf E.O against MDR A. baumannii wound infections and their underlying mechanism and to be further tested clinically as treatment for MDR A. baumannii infections.

中文翻译：

---

皮门塔油作为鲍曼不动杆菌伤口感染的潜在治疗方法：关于其化学成分的体外和体内生物测定

细菌生物膜有助于抗生素耐药性。开发更受自然来源青睐的抗生物膜剂是治疗高毒力多药耐药性（MDR）细菌菌株的一种潜在方法。研究了皮menta dioica和Pimenta racemosa精油（E.Os）的抗菌和抗生物膜活性与其化学成分的关系，以及它们在小鼠模型中治疗鲍曼不动杆菌伤口感染的能力；浓度为0.05 µg·mL ^-1的P. dioica叶EO有效抑制和消除了鲍曼不动杆菌形成的生物膜，分别达到了85％和34％。无论P. diocia和消旋假单胞菌叶E.Os在2.08 µg·mL ^-1的6h内对鲍曼不动杆菌具有杀菌作用。此外，发现小鼠伤口感染模型中鲍曼不动杆菌的微生物负荷显着降低。此外，气相色谱-质谱分析表明之间的定性和定量的差异P.总状和P.腿子叶和浆果E.Os. 单萜碳氢化合物，含氧单萜和酚类化合物是检测到的主要类别。β-月桂烯，柠檬烯，1,8-桉树脑和丁香酚是最丰富的挥发物。而倍半萜在皮门塔被发现是次要成分浆果EO; 我们的发现表明，Pimenta叶片EO对MDR鲍曼不动杆菌伤口感染的潜在抗菌活性及其潜在机理，并作为MDR A.鲍曼不动杆菌感染的治疗方法进行临床进一步测试。